Honokiol induces cytotoxic and cytostatic effects in malignant melanoma cancer cells

被引:42
作者
Kaushik, Gaurav [3 ]
Ramalingam, Satish [1 ,2 ]
Subramaniam, Dharmalingam [1 ,2 ]
Rangarajanb, Parthasarthy [1 ,2 ]
Protti, Piero [3 ]
Rammamoorthy, Prabhu [1 ,2 ]
Anant, Shrikant [1 ,2 ]
Mammen, Joshua M. V. [1 ,2 ,3 ]
机构
[1] Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66103 USA
[2] Univ Kansas, Ctr Canc, Kansas City, KS 66160 USA
[3] Univ Kansas, Med Ctr, Dept Surg, Kansas City, KS 66103 USA
基金
美国国家卫生研究院;
关键词
Melanoma; AKT; Cyclin D1; Cell-cycle arrest; mTOR; gamma-secretase; TUMOR-INITIATING CELLS; CYCLIN D1; COLON-CANCER; CUTANEOUS MELANOMA; EPITHELIAL-CELLS; KINASE; EXPRESSION; INHIBITORS; COMBINATION; ACTIVATION;
D O I
10.1016/j.amjsurg.2012.09.001
中图分类号
R61 [外科手术学];
学科分类号
摘要
BACKGROUND: Melanomas are aggressive neoplasms with limited therapeutic options. Therefore, developing new therapies with low toxicity is of utmost importance. Honokiol is a natural compound that recently has shown promise as an effective anticancer agent. METHODS: The effect of honokiol on melanoma cancer cells was assessed in vitro. Proliferation and physiologic changes were determined using hexosaminidase assay and transmission electron microscopy. Protein expression was assessed by immunoblotting. RESULTS: Honokiol treatment inhibited cell proliferation and induced death. Electron microscopy showed autophagosome formation. Reduced levels of cyclin D1 accompanied cell-cycle arrest. Honokiol also decreased phosphorylation of AKT (known as protein kinase B) and mammalian target of rapamycin, and inhibited gamma-secretase activity by down-regulating the expression of gamma-secretase complex proteins, especially anterior pharynx-defective 1. CONCLUSIONS: Honokiol is highly effective in inhibiting melanoma cancer cells by attenuating AKT/mammalian target of rapamycin and Notch signaling. These studies warrant further clinical evaluation for honokiol alone or with present chemotherapeutic regimens for the treatment of melanomas. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:868 / 873
页数:6
相关论文
共 33 条
[1]   Honokiol Arrests Cell Cycle, Induces Apoptosis, and Potentiates the Cytotoxic Effect of Gemcitabine in Human Pancreatic Cancer Cells [J].
Arora, Sumit ;
Bhardwaj, Arun ;
Srivastava, Sanjeev K. ;
Singh, Seema ;
McClellan, Steven ;
Wang, Bin ;
Singh, Ajay P. .
PLOS ONE, 2011, 6 (06)
[2]   Topical treatment with inhibitors of the phosphatidylinositol 3′-kinase/akt and raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodericient mice [J].
Bedogni, B ;
O'Neill, MS ;
Welford, SM ;
Bouley, DM ;
Giaccia, AJ ;
Denko, NC ;
Powell, MB .
CANCER RESEARCH, 2004, 64 (07) :2552-2560
[3]  
Bello L, 2001, CANCER RES, V61, P7501
[4]   High levels of MMP-1 expression in the absence of the 2G single nucleotide polymorphism is mediated by p38 and ERK1/2 mitogen-activated protein kinases in VMM5 melanoma cells [J].
Benbow, U ;
Tower, GB ;
Wyatt, CA ;
Buttice, G ;
Brinckerhoff, CE .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2002, 86 (02) :307-319
[5]   Akt and mutant V600EB-Raf cooperate to promote early melanoma development [J].
Cheung, Mitchefl ;
Sharma, Arati ;
Madhunapantula, SubbaRao V. ;
Robertson, Gavin P. .
CANCER RESEARCH, 2008, 68 (09) :3429-3439
[6]   Distinct sets of genetic alterations in melanoma [J].
Curtin, JA ;
Fridlyand, J ;
Kageshita, T ;
Patel, HN ;
Busam, KJ ;
Kutzner, H ;
Cho, KH ;
Aiba, S ;
Bröcker, EB ;
LeBoit, PE ;
Pinkel, D ;
Bastian, BC .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (20) :2135-2147
[7]   Mutations of the BRAF gene in human cancer [J].
Davies, H ;
Bignell, GR ;
Cox, C ;
Stephens, P ;
Edkins, S ;
Clegg, S ;
Teague, J ;
Woffendin, H ;
Garnett, MJ ;
Bottomley, W ;
Davis, N ;
Dicks, N ;
Ewing, R ;
Floyd, Y ;
Gray, K ;
Hall, S ;
Hawes, R ;
Hughes, J ;
Kosmidou, V ;
Menzies, A ;
Mould, C ;
Parker, A ;
Stevens, C ;
Watt, S ;
Hooper, S ;
Wilson, R ;
Jayatilake, H ;
Gusterson, BA ;
Cooper, C ;
Shipley, J ;
Hargrave, D ;
Pritchard-Jones, K ;
Maitland, N ;
Chenevix-Trench, G ;
Riggins, GJ ;
Bigner, DD ;
Palmieri, G ;
Cossu, A ;
Flanagan, A ;
Nicholson, A ;
Ho, JWC ;
Leung, SY ;
Yuen, ST ;
Weber, BL ;
Siegler, HF ;
Darrow, TL ;
Paterson, H ;
Marais, R ;
Marshall, CJ ;
Wooster, R .
NATURE, 2002, 417 (6892) :949-954
[8]   Specificity and mechanism of action of some commonly used protein kinase inhibitors [J].
Davies, SP ;
Reddy, H ;
Caivano, M ;
Cohen, P .
BIOCHEMICAL JOURNAL, 2000, 351 (351) :95-105
[9]  
Donnellan R, 1998, J CLIN PATHOL-MOL PA, V51, P1
[10]   Identification of a novel inhibitor of mitogen-activated protein kinase kinase [J].
Favata, MF ;
Horiuchi, KY ;
Manos, EJ ;
Daulerio, AJ ;
Stradley, DA ;
Feeser, WS ;
Van Dyk, DE ;
Pitts, WJ ;
Earl, RA ;
Hobbs, F ;
Copeland, RA ;
Magolda, RL ;
Scherle, PA ;
Trzaskos, JM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (29) :18623-18632